Colorectal metastases confined to the liver: A unique opportunity?

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 15, 2003, Pages 34-39

  Venook, Alan P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DEXAMETHASONE; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

CANCER RECURRENCE; CANCER SURVIVAL; CATHETER ABLATION; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DISSEMINATED CANCER; DRUG EFFICACY; HUMAN; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0141993872     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00403-2     Document Type: Conference Paper

References (34)

1. Kemeny M: Hepatic artery infusion of chemotherapy as a treatment for hepatic metastases from colorectal cancer. Cancer J 8:S82-S88, 2002 (suppl 1)
2. Venook AP, Warren RS: Therapeutic approaches to metastasis confined to the liver. Curr Oncol Rep 3:109-115, 2001
3. Fong Y, Cohen AM, Fortner JG, et al: Liver resection for colorectal metastases. J Clin Oncol 15:938-946, 1997
4. Glasgow RE, Showstack JA, Katz PP, et al: The relationship between hospital volume and outcomes of hepatic resection for hepatocellular carcinoma. Arch Surg 134:30-35, 1999
5. Luna-Perez P, Rodriguez-Coria DF, Arroyo B, et al: The natural history of liver metastases from colorectal cancer. Arch Med Res 29:319-324, 1998
6. Jarnagin WR, Fong Y, Ky A, et al: Liver resection for metastatic colorectal cancer: Assessing the risk of occult irresectable disease. J Am Coll Surg 188:33-42, 1999
7. Bilchik AJ, Rose DM, Allegra DP, et al: Radiofrequency ablation: A minimally invasive technique with multiple applications. Cancer J Sci Am 5:356-361, 1999
8. Onik G, Rubinsky B, Zemel R, et al: Ultrasound-guided hepatic cryosurgery in the treatment of metastatic colon carcinoma. Preliminary results. Cancer 67:901-907, 1991
9. Breedis C, Young G: The blood supply of neoplasms in the liver. Am J Pathol 30:969-985, 1954
10. Collins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498-504, 1984
11. Chang AE, Schneider PD, Sugarbaker PH, et al: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206:685-693, 1987
12. Martin JK Jr, O'Connell MJ, Wieand HS, et al: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 125:1022-1027, 1990
13. Hohn DC, Stagg RJ, Friedman MA, et al: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern Oncology Group trial. J Clin Oncol 7:1646-1654, 1989
14. Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107:459-465, 1987
15. Allen-Mersh TG, Earlam S, Fordy C, et al: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344:1255-1260, 1994
16. Rougier P, Laplanche A, Huguier M, et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 10:1112-1118, 1992
17. Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88:252-258, 1996
18. Kemeny N, Conti JA, Cohen A, et al: Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 12:2288-2295, 1994
19. Belluco C, Guillem JG, Kemeny N, et al: p53 nuclear protein overexpression in colorectal cancer: A dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14:2696-2701, 1996
20. Kemeny N, Huang Y, Cohen AM, et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341:2039-2048, 1999
21. Kemeny MM, Adak S, Gray B, et al: Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-An intergroup study. J Clin Oncol 20:1499-1505, 2002
22. Lorenz M, Muller HH, Schramm H, et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228:756-762, 1998
23. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
24. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
25. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
26. Goldberg RM, Morton RF, Sargent DJ, et al: N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5-FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol 21:128a, 2002 (abstr 511)
27. Bismuth H, Adam R, Levi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-520 discussion 520-522, 1996
28. Adam R, Avisar E, Ariche A, et al: Five-year survival following hepatic resection after neoadjuvant therapy for non-resectable colorectal [liver] metastases. Ann Surg Oncol 8:347-353, 2001
29. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
30. Alberts SR, Horvath W, Donohue JH, et al: Oxaliplatin (OXAL), 5-fluorouracil (5FU), and leucovorin (CF) for patients (pts) with liver only metastases (mets) from colorectal cancer (CRC): A North Central Cancer Treatment Group (NCCTG) phase II study. Proc Am Soc Clin Oncol 20:129a, 2001 (abstr 511)
31. Tournigand C, Louvet C, Quinaux E, et al: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 20:124a, 2001 (abstr 494)
32. Grothey A, Deschler B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21:129a, 2002 (abstr 512)
33. Ron IG, Kemeny NE, Tong B, et al: Phase I/II study of escalating doses of systemic irinotecan (CPT-11) with hepatic arterial infusion of floxuridine (FUDR) and dexamethasone (D), with or without cryosurgery for patients with unresectable hepatic metastases from colorectal cancer. Proc Am Soc Clin Oncol 18:236a, 1999 (abstr 908)
34. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327, 2000